{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:44:57Z","timestamp":1778546697884,"version":"3.51.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,5,25]],"date-time":"2016-05-25T00:00:00Z","timestamp":1464134400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s40261-016-0413-z","type":"journal-article","created":{"date-parts":[[2016,5,25]],"date-time":"2016-05-25T07:15:46Z","timestamp":1464160546000},"page":"499-508","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Tafluprost Ophthalmic Solution 0.0015\u00a0%: A Review in Glaucoma and Ocular Hypertension"],"prefix":"10.1007","volume":"36","author":[{"given":"Gillian M.","family":"Keating","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,5,25]]},"reference":[{"key":"413_CR1","unstructured":"European Glaucoma Society. Terminology and guidelines for glaucoma. 2014. http:\/\/www.eugs.org . Accessed 3 Mar 2016."},{"issue":"1","key":"413_CR2","doi-asserted-by":"crossref","first-page":"P41","DOI":"10.1016\/j.ophtha.2015.10.053","volume":"123","author":"BE Prum","year":"2016","unstructured":"Prum BE, Rosenberg LF, Gedde SJ, et al. Primary open-angle glaucoma: preferred practice pattern. Ophthalmology. 2016;123(1):P41\u2013111.","journal-title":"Ophthalmology"},{"key":"413_CR3","unstructured":"Japan Glaucoma Society. Guidelines for glaucoma (2nd edition). 2006. http:\/\/www.ryokunaisho.jp\/english\/Guidelines_for_Glaucoma.pdf . Accessed 7 Mar 2016."},{"issue":"5","key":"413_CR4","doi-asserted-by":"crossref","first-page":"529","DOI":"10.4103\/0301-4738.133481","volume":"62","author":"BJ Song","year":"2014","unstructured":"Song BJ, Caprioli J. New directions in the treatment of normal tension glaucoma. Indian J Ophthalmol. 2014;62(5):529\u201337.","journal-title":"Indian J Ophthalmol"},{"issue":"9","key":"413_CR5","first-page":"1641","volume":"111","author":"A Iwase","year":"2004","unstructured":"Iwase A, Suzuki Y, Araie M, et al. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. Ophthalmology. 2004;111(9):1641\u20138.","journal-title":"Ophthalmology"},{"issue":"12","key":"413_CR6","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1136\/bjophthalmol-2013-303528","volume":"97","author":"M Irkec","year":"2013","unstructured":"Irkec M, Bozkurt B, Mocan MC. Are preservatives necessary to improve efficacy of some glaucoma drops? Br J Ophthalmol. 2013;97(12):1493\u20134.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"413_CR7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4265\/bio.17.121","volume":"17","author":"M Ayaki","year":"2012","unstructured":"Ayaki M, Iwasawa A, Niwano Y. Cell viability score as an integrated indicator for cytotoxicity of benzalkonium chloride-containing antiglaucoma eyedrops. Biocontrol Sci. 2012;17(3):121\u20138.","journal-title":"Biocontrol Sci."},{"issue":"Suppl 242","key":"413_CR8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1755-3768.2008.01381.x","volume":"86","author":"T Hamacher","year":"2008","unstructured":"Hamacher T, Airaksinen J, Saarela V, et al. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis. Acta Ophthalmol (Copenh). 2008;86(Suppl 242):14\u20139.","journal-title":"Acta Ophthalmol (Copenh)."},{"issue":"4","key":"413_CR9","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.exer.2003.12.007","volume":"78","author":"Y Takagi","year":"2004","unstructured":"Takagi Y, Nakajima T, Shimazaki A, et al. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res. 2004;78(4):767\u201376.","journal-title":"Exp Eye Res"},{"key":"413_CR10","unstructured":"Santen UK Ltd. Saflutan (tafluprost) 15 micrograms\/ml eye drops, solution: UK summary of product characteristics. 2015. http:\/\/www.medicines.org.uk\/emc\/ . Accessed 4 Mar 2016."},{"issue":"8","key":"413_CR11","doi-asserted-by":"crossref","first-page":"400","DOI":"10.5414\/CPP46400","volume":"46","author":"A Sutton","year":"2008","unstructured":"Sutton A, Gouws P, Ropo A. Tafluprost, a new potent prostanoid receptor agonist: a dose-response study on pharmacodynamics and tolerability in healthy volunteers. Int J Clin Pharmacol Ther. 2008;46(8):400\u20136.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"4","key":"413_CR12","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s10384-010-0828-7","volume":"54","author":"H Mochizuki","year":"2010","unstructured":"Mochizuki H, Itakura H, Yokoyama T, et al. Twenty-four-hour ocular hypotensive effects of 0.0015\u00a0% tafluprost and 0.005\u00a0% latanoprost in healthy subjects. Jpn J Ophthalmol. 2010;54(4):286\u201390.","journal-title":"Jpn J Ophthalmol"},{"issue":"1","key":"413_CR13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1089\/jop.2009.0066","volume":"26","author":"CE Traverso","year":"2010","unstructured":"Traverso CE, Ropo A, Papadia M, et al. A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of tafluprost compared with latanoprost. J Ocul Pharmacol Ther. 2010;26(1):97\u2013104.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"5","key":"413_CR14","first-page":"691","volume":"27","author":"Y Fukano","year":"2010","unstructured":"Fukano Y, Odani-Kawabata N, Nakamura M, et al. Intraocular penetration and intraocular pressure-lowering effect of new formulation 0.0015\u00a0% tafluprost ophthalmic solution with reduced benzalkonium chloride [in Japanese]. Atarashii Ganka. 2010;27(5):691\u20134.","journal-title":"Atarashii Ganka."},{"issue":"11","key":"413_CR15","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s12325-010-0070-1","volume":"27","author":"DA Ammar","year":"2010","unstructured":"Ammar DA, Noecker RJ, Kahook MY. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. Adv Ther. 2010;27(11):837\u201345.","journal-title":"Adv Ther."},{"issue":"6","key":"413_CR16","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1248\/yakushi.130.867","volume":"130","author":"H Asada","year":"2010","unstructured":"Asada H, Takaoka-Shichijo Y, Nakamura M, et al. Optimization of benzalkonium chloride concentration in 0.0015\u00a0% tafluprost ophthalmic solution from the points of ocular surface safety and preservative efficacy [in Japanese]. Yakugaku Zasshi. 2010;130(6):867\u201371.","journal-title":"Yakugaku Zasshi"},{"issue":"9","key":"413_CR17","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1167\/iovs.12-9685","volume":"53","author":"S Nakagawa","year":"2012","unstructured":"Nakagawa S, Usui T, Yokoo S, et al. Toxicity evaluation of antiglaucoma drugs using stratified human cultivated corneal epithelial sheets. Invest Ophthalmol Vis Sci. 2012;53(9):5154\u201360.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"413_CR18","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3341\/kjo.2013.27.6.446","volume":"27","author":"EJ Kim","year":"2013","unstructured":"Kim EJ, Kim Y-H, Kang SH, et al. In vitro effects of preservative-free and preserved prostaglandin analogs on primary cultured human conjunctival fibroblast cells. Korean J Ophthalmol. 2013;27(6):446\u201353.","journal-title":"Korean J Ophthalmol"},{"issue":"2","key":"413_CR19","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/ceo.12390","volume":"43","author":"C Chang","year":"2015","unstructured":"Chang C, Zhang AQ, Kagan DB, et al. Mechanisms of benzalkonium chloride toxicity in a human trabecular meshwork cell line and the protective role of preservative-free tafluprost. Clin Exp Ophthalmol. 2015;43(2):164\u201372.","journal-title":"Clin Exp Ophthalmol."},{"issue":"2","key":"413_CR20","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1089\/jop.2009.0100","volume":"26","author":"T Akaishi","year":"2010","unstructured":"Akaishi T, Kurashima H, Odani-Kawabata N, et al. Effects of repeated administrations of tafluprost, latanoprost, and travoprost on optic nerve head blood flow in conscious normal rabbits. J Ocul Pharmacol Ther. 2010;26(2):181\u20136.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"6","key":"413_CR21","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.exer.2010.09.004","volume":"91","author":"H Kurashima","year":"2010","unstructured":"Kurashima H, Watabe H, Sato N, et al. Effects of prostaglandin F2\u03b1 analogues on endothelin-1-induced impairment of rabbit ocular blood flow: comparison among tafluprost, travoprost, and latanoprost. Exp Eye Res. 2010;91(6):853\u20139.","journal-title":"Exp Eye Res"},{"issue":"1","key":"413_CR22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5935\/0004-2749.20160010","volume":"79","author":"AT Giannico","year":"2016","unstructured":"Giannico AT, Lima L, Shaw GC, et al. Effects of prostaglandin analogs on blood flow velocity and resistance in the ophthalmic artery of rabbits. Arq Bras Oftalmol. 2016;79(1):33\u20136.","journal-title":"Arq Bras Oftalmol."},{"issue":"8","key":"413_CR23","first-page":"1115","volume":"27","author":"J Ishigaki","year":"2010","unstructured":"Ishigaki J, Miyake S, Harino S, et al. Effect of tafluprost on choroidal blood flow in glaucoma [in Japanese]. Atarashii Ganka. 2010;27(8):1115\u20138.","journal-title":"Atarashii Ganka."},{"issue":"4","key":"413_CR24","first-page":"475","volume":"65","author":"T Sugiyama","year":"2011","unstructured":"Sugiyama T, Shibata M, Kojima S, et al. Changes in microcirculation in the optic nerve head following topical tafluprost treatment in eyes with primary open-angle glaucoma [in Japanese]. Rinsho Ganka. 2011;65(4):475\u20139.","journal-title":"Rinsho Ganka."},{"issue":"5","key":"413_CR25","first-page":"741","volume":"69","author":"M Shibata","year":"2015","unstructured":"Shibata M, Sugiyama T, Kojima S, et al. Effects on visual field, morphology and microcirculation of optic nerve head following tafluprost treatment for 3\u00a0years in patients with glaucoma [in Japanese]. Rinsho Ganka. 2015;69(5):741\u20137.","journal-title":"Rinsho Ganka."},{"key":"413_CR26","unstructured":"Santen Pharmaceutical Co Ltd. Tapros\u00ae (tafluprost) ophthalmic solution 0.0015\u00a0%: Japanese prescribing information. 2015."},{"issue":"5","key":"413_CR27","first-page":"436","volume":"114","author":"Y Kuwayama","year":"2010","unstructured":"Kuwayama Y, Komemushi S. Intraocular pressure lowering effect of 0.0015% tafluprost as compared to placebo in patients with normal tension glaucoma: randomized, double-blind, multicenter, phase III study [in Japanese]. Nip GG Zass. 2010;114(5):436\u201343.","journal-title":"Nip GG Zass"},{"issue":"11","key":"413_CR28","first-page":"1595","volume":"25","author":"Y Kuwayama","year":"2008","unstructured":"Kuwayama Y, Komemushi S. Phase III confirmatory study of 0.0015\u00a0% DE-085 (tafluprost) ophthalmic solution as compared to 0.005\u00a0% latanoprost ophthalmic solution in patients with open-angle glaucoma or ocular hypertension [in Japanese]. Atarashii Ganka. 2008;25(11):1595\u2013602.","journal-title":"Atarashii Ganka."},{"issue":"6","key":"413_CR29","first-page":"913","volume":"66","author":"T Eguro","year":"2012","unstructured":"Eguro T, Shoji N, Kasahara M, et al. A parallel-group comparison of hypotensive effect of latanoprost and tafluprost [in Japanese]. Rinsho Ganka. 2012;66(6):913\u20136.","journal-title":"Rinsho Ganka."},{"issue":"1","key":"413_CR30","first-page":"85","volume":"65","author":"M Adachi","year":"2011","unstructured":"Adachi M. Ocular hypotensive effect after switching from topical latanoprost to tafluprost [in Japanese]. Rinsho Ganka. 2011;65(1):85\u20139.","journal-title":"Rinsho Ganka."},{"issue":"6","key":"413_CR31","first-page":"827","volume":"27","author":"J Kozaki","year":"2010","unstructured":"Kozaki J, Unoki K, Adachi M, et al. Efficacy of switching from latanoprost to tafluprost in patients with normal-tension glaucoma [in Japanese]. Atarashii Ganka. 2010;27(6):827\u201330.","journal-title":"Atarashii Ganka."},{"issue":"1","key":"413_CR32","first-page":"113","volume":"30","author":"T Nakamuro","year":"2013","unstructured":"Nakamuro T, Nakano S, Kiyosaki K, et al. Comparison of efficacy and safety of tafluprost and latanoprost in patients with normal tension glaucoma [in Japanese]. Atarashii Ganka. 2013;30(1):113\u20136.","journal-title":"Atarashii Ganka."},{"issue":"10","key":"413_CR33","first-page":"1685","volume":"64","author":"S Takeda","year":"2010","unstructured":"Takeda S, Koyama H, Matsubara M. Efficacy of switching from latanoprost to tafluprost for glaucoma [in Japanese]. Rinsho Ganka. 2010;64(10):1685\u20139.","journal-title":"Rinsho Ganka."},{"key":"413_CR34","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.2147\/OPTH.S33414","volume":"6","author":"T Mizoguchi","year":"2012","unstructured":"Mizoguchi T, Ozaki M, Unoki K, et al. A randomized crossover study comparing tafluprost 0.0015\u00a0% with travoprost 0.004\u00a0% in patients with normal-tension glaucoma. Clin Ophthalmol. 2012;6:1579\u201384.","journal-title":"Clin Ophthalmol"},{"issue":"12","key":"413_CR35","first-page":"1727","volume":"27","author":"S Nakano","year":"2010","unstructured":"Nakano S, Kubota T. Long-term efficacy of tafluprost after switching from latanoprost [in Japanese]. Atarashii Ganka. 2010;27(12):1727\u201330.","journal-title":"Atarashii Ganka."},{"issue":"4","key":"413_CR36","first-page":"568","volume":"28","author":"A Sone","year":"2011","unstructured":"Sone A, Katsushima H, Funahashi K, et al. Efficacy and safety of 0.0015\u00a0% tafluprost ophthalmic solution in normal-tension glaucoma [in Japanese]. Atarashii Ganka. 2011;28(4):568\u201370.","journal-title":"Atarashii Ganka."},{"issue":"6","key":"413_CR37","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s10384-011-0082-7","volume":"55","author":"T Nakano","year":"2011","unstructured":"Nakano T, Yoshikawa K, Kimura T, et al. Efficacy and safety of tafluprost in normal-tension glaucoma with intraocular pressure of 16\u00a0mmHg or less. Jpn J Ophthalmol. 2011;55(6):605\u201313.","journal-title":"Jpn J Ophthalmol"},{"issue":"7","key":"413_CR38","first-page":"967","volume":"27","author":"Y Miyagawa","year":"2010","unstructured":"Miyagawa Y, Yamazaki H, Nakazawa M. Short-term efficacy of tafluprost monotherapy for untreated glaucoma [in Japanese]. Atarashii Ganka. 2010;27(7):967\u20139.","journal-title":"Atarashii Ganka."},{"issue":"4","key":"413_CR39","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s12325-014-0109-9","volume":"31","author":"Y Kuwayama","year":"2014","unstructured":"Kuwayama Y, Nomura A. Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety. Adv Ther. 2014;31(4):461\u201371.","journal-title":"Adv Ther."},{"issue":"7","key":"413_CR40","first-page":"1043","volume":"28","author":"F Okada","year":"2011","unstructured":"Okada F, Inoue K, Wakakura M, et al. Ocular hypotensive effects and safety of tafluprost in normal-tension glaucoma [in Japanese]. Atarashii Ganka. 2011;28(7):1043\u20136.","journal-title":"Atarashii Ganka."},{"issue":"8","key":"413_CR41","first-page":"597","volume":"7","author":"S Watanabe","year":"2014","unstructured":"Watanabe S, Kimura I, Nakazawa Y, et al. The investigation of the clinical results of tafluprost in normal-tension glaucoma [in Japanese]. Folia Japonica de Ophthalmologica Clinica. 2014;7(8):597\u2013602.","journal-title":"Folia Japonica de Ophthalmologica Clinica."},{"issue":"8","key":"413_CR42","first-page":"1161","volume":"28","author":"T Nakauchi","year":"2011","unstructured":"Nakauchi T, Okami T, Yamagishi K. Long-term intraocular pressure-lowering effect of tafluprost in patients with normal-tension glaucoma [in Japanese]. Atarashii Ganka. 2011;28(8):1161\u20135.","journal-title":"Atarashii Ganka."},{"key":"413_CR43","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.2147\/OPTH.S46340","volume":"7","author":"K Inoue","year":"2013","unstructured":"Inoue K, Tanaka A, Tomita G. Effects of tafluprost treatment for 3\u00a0years in patients with normal-tension glaucoma. Clin Ophthalmol. 2013;7:1411\u20136.","journal-title":"Clin Ophthalmol."},{"issue":"2","key":"413_CR44","first-page":"95","volume":"51","author":"J Ge","year":"2015","unstructured":"Ge J, Li X, Sun X. Randomized parallel group study of 0.0015\u00a0% tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension (comparison with 0.005\u00a0% latanoprost ophthalmic solution) [in Chinese]. Zhonghua Yan Ke Za Zhi. 2015;51(2):95\u2013102.","journal-title":"Zhonghua Yan Ke Za Zhi"},{"issue":"8","key":"413_CR45","first-page":"1131","volume":"29","author":"Y Tanabe","year":"2012","unstructured":"Tanabe Y, Kanno M, Yamashita H. Intraocular pressure-lowering effect of travoprost, tafluprost and bimatoprost in normal tension glaucoma [in Japanese]. Atarashii Ganka. 2012;29(8):1131\u20135.","journal-title":"Atarashii Ganka."},{"issue":"3","key":"413_CR46","first-page":"383","volume":"27","author":"K Inoue","year":"2010","unstructured":"Inoue K, Masumoto M, Wakakura M, et al. Ocular hypotensive effects of latanoprost, travoprost and tafluprost [in Japanese]. Atarashii Ganka. 2010;27(3):383\u20136.","journal-title":"Atarashii Ganka."},{"issue":"2","key":"413_CR47","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1089\/jop.2015.0086","volume":"32","author":"K Inoue","year":"2016","unstructured":"Inoue K, Setogawa A, Tomita G. Nonresponders to prostaglandin analogs among normal-tension glaucoma patients. J Ocul Pharmacol Ther. 2016;32(2):90\u20136.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"3","key":"413_CR48","first-page":"287","volume":"66","author":"S Yoshida","year":"2012","unstructured":"Yoshida S. Adherence to topical tafluprost treatment for one year in glaucoma patients [in Japanese]. Rinsho Ganka. 2012;66(3):287\u20139.","journal-title":"Rinsho Ganka."},{"issue":"1","key":"413_CR49","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1755-3768.2010.01862.x","volume":"88","author":"H Uusitalo","year":"2010","unstructured":"Uusitalo H, Pillunat LE, Ropo A. Efficacy and safety of tafluprost 0.0015\u00a0% versus latanoprost 0.005\u00a0% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study. Acta Ophthalmol. 2010;88(1):12\u20139.","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"413_CR50","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s10384-012-0199-3","volume":"57","author":"T Yoshino","year":"2013","unstructured":"Yoshino T, Fukuchi T, Togano T, et al. Eyelid and eyelash changes due to prostaglandin analog therapy in unilateral treatment cases. Jpn J Ophthalmol. 2013;57(2):172\u20138.","journal-title":"Jpn J Ophthalmol"},{"issue":"11","key":"413_CR51","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/eye.2012.195","volume":"26","author":"K Inoue","year":"2012","unstructured":"Inoue K, Shiokawa M, Higa R, et al. Adverse periocular reactions to five types of prostaglandin analogs. Eye (London, England). 2012;26(11):1465\u201372.","journal-title":"Eye (London, England)"},{"issue":"8","key":"413_CR52","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/IJG.0b013e31824d8d7c","volume":"22","author":"K Inoue","year":"2013","unstructured":"Inoue K, Shiokawa M, Wakakura M, et al. Deepening of the upper eyelid sulcus caused by 5 types of prostaglandin analogs. J Glaucoma. 2013;22(8):626\u201331.","journal-title":"J Glaucoma"},{"issue":"2","key":"413_CR53","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s10384-013-0299-8","volume":"58","author":"R Sakata","year":"2014","unstructured":"Sakata R, Shirato S, Miyata K, et al. Incidence of deepening of the upper eyelid sulcus on treatment with a tafluprost ophthalmic solution. Jpn J Ophthalmol. 2014;58(2):212\u20137.","journal-title":"Jpn J Ophthalmol"},{"issue":"4","key":"413_CR54","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1089\/jop.2013.0132","volume":"30","author":"T Kumagami","year":"2014","unstructured":"Kumagami T, Wakiyama H, Kusano M, et al. Comparison of corneal safety and intraocular pressure-lowering effect of tafluprost ophthalmic solution with other prostaglandin ophthalmic solutions. J Ocul Pharmacol Ther. 2014;30(4):340\u20135.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"6","key":"413_CR55","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1097\/IJG.0000000000000020","volume":"24","author":"K Suzuki","year":"2015","unstructured":"Suzuki K, Teranishi S, Sagara T, et al. Safety and efficacy of benzalkonium chloride-optimized tafluprost in Japanese glaucoma patients with existing superficial punctate keratitis. J Glaucoma. 2015;24(6):e145\u201350.","journal-title":"J Glaucoma"},{"issue":"3","key":"413_CR56","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1089\/jop.2014.0104","volume":"31","author":"T Kanamoto","year":"2015","unstructured":"Kanamoto T, Kiuchi Y, Tanito M, et al. Comparison of the toxicity profile of benzalkonium chloride-preserved tafluprost and sofZia-preserved travoprost applied to the ocular surface. J Ocul Pharmacol Ther. 2015;31(3):156\u201364.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"7","key":"413_CR57","first-page":"959","volume":"68","author":"T Nakamura","year":"2014","unstructured":"Nakamura T, Kanamoto T, Komatsu N, et al. Satisfaction and subjective symptoms after instillation of tafluprost or travoprost for twelve weeks each [in Japanese]. Rinsho Ganka. 2014;68(7):959\u201366.","journal-title":"Rinsho Ganka."},{"key":"413_CR58","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2147\/OPTH.S24248","volume":"6","author":"SS Ermi\u015f","year":"2012","unstructured":"Ermi\u015f SS. Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma. Clin Ophthalmol. 2012;6:673\u20138.","journal-title":"Clin Ophthalmol."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-016-0413-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-016-0413-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-016-0413-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:41:00Z","timestamp":1559490060000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-016-0413-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,25]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["413"],"URL":"https:\/\/doi.org\/10.1007\/s40261-016-0413-z","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,25]]}}}